December 20th 2021, 8:00pm
Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.
December 12th 2021, 8:00pm
Study results showed that pathologic complete response rates were not significantly different between Black and White patients with high-risk breast cancer, but disparities still exist for other treatment outcomes.
December 11th 2021, 3:00pm
Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.
December 10th 2021, 10:00pm
A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.
December 10th 2021, 5:00pm
The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.
December 10th 2021, 2:00pm
Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.
December 9th 2021, 10:00pm
Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.
December 9th 2021, 8:00pm
Treatment modifications in the pre-surgery setting led to a lower rate of pathologic complete response in Black patients with breast cancer, the researchers found.
December 8th 2021, 10:00pm
The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
December 8th 2021, 4:00pm
Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.
What Patients With Lung Cancer Need to Know About EGFR PACC Mutations
FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer
Lunsumio plus Polivy Associated With Responses in MCL
Standing Up to Cancer with Lynch Syndrome